Get the Stockscreener App
6.6871
0.57%
-0.0329
Biocryst Pharmaceuticals Inc stock is traded at $6.6871, with a volume of 3.53M.
It is down -0.57% in the last 24 hours and down -12.20% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$6.72
Open:
$6.69
24h Volume:
3.53M
Relative Volume:
0.79
Market Cap:
$1.41B
Revenue:
$557.51M
Net Income/Loss:
$-35.71M
P/E Ratio:
-37.15
EPS:
-0.18
Net Cash Flow:
$15.50M
1W Performance:
-6.81%
1M Performance:
-12.20%
6M Performance:
-22.75%
1Y Performance:
-12.31%
1-Day Range:
$6.63
$6.8654
1-Week Range:
$6.46
$7.17
52-Week Range:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
6.69 | 1.42B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Resumed | TD Cowen | Buy |
| Oct-01-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
Astria stockholders approve acquisition by BioCryst - Investing.com Nigeria
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria stockholders vote to approve acquisition by BioCryst - marketscreener.com
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
BioCryst: A Changed And Interesting Thesis For 2026 (NASDAQ:BCRX) - Seeking Alpha
Campbell & CO Investment Adviser LLC Decreases Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Does BioCryst (BCRX) 2026 Revenue Guidance Reframe the ORLADEYO Growth Story for Investors? - simplywall.st
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its New 2026 Revenue Guidance - Sahm
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.8%What's Next? - MarketBeat
Stock Recap: What is The OLB Group Incs P E ratio telling us2025 Macro Impact & Smart Money Movement Alerts - baoquankhu1.vn
(BCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Aug Volume: Why BioCryst Pharmaceuticals Inc stock could outperform in 2025 - Bộ Nội Vụ
Portfolio Update: Will BioCryst Pharmaceuticals Inc stock outperform growth indexes2025 Momentum Check & Reliable Momentum Entry Alerts - Bộ Nội Vụ
BioCryst stock holds steady as Cantor Fitzgerald reaffirms Overweight rating By Investing.com - Investing.com UK
Citizens reiterates Market Outperform rating on BioCryst Pharma stock By Investing.com - Investing.com Canada
BioCryst reports $563 million in ORLADEYO revenue for 2025 By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - MarketBeat
Investment Report: Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zoneMarket Sentiment Review & Weekly Watchlist of Top Performers - Bộ Nội Vụ
Portfolio Update: Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsWeekly Investment Report & AI Enhanced Trading Signals - Bộ Nội Vụ
BCRX: ORLADEYO growth, Astria acquisition, and pipeline advances drive rare disease expansion - TradingView — Track All Markets
BioCryst reports $563 million in ORLADEYO revenue for 2025 - Investing.com
BCRX Forecasts FY26 ORLADEYO Revenue in Range of $625M-$645M - GuruFocus
BCRX: ORLADEYO Sees Strong Revenue Growth in Q4 2025 - GuruFocus
(BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M - marketscreener.com
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - The Manila Times
Once-daily pill for HAE patients now brings in $601M a year - Stock Titan
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play - MSN
Published on: 2026-01-10 14:45:46 - Улправда
FDA approves seven NMEs in December - biocentury.com
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility - Sahm
BioCryst Pharmaceuticals, Inc.Common Stock (NQ: BCRX - FinancialContent
BioCryst to buy Astria Therapeutics for $13 per share (update) - MSN
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack - Investing.com Nigeria
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack By Investing.com - Investing.com South Africa
BioCryst Raises Price of Key ORLADEYO Treatment - TipRanks
BioCryst Pharmaceuticals Increases ORLADEYO® Price - TradingView — Track All Markets
Is BioCryst Pharmaceuticals Inc. stock oversold or undervalued2025 Trading Recap & AI Forecasted Entry and Exit Points - ulpravda.ru
How BioCryst Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - Улправда
Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsGap Down & Free Verified High Yield Trade Plans - ulpravda.ru
CEO Moves: Will BioCryst Pharmaceuticals Inc. stock deliver long term returnsPortfolio Update Report & Expert Verified Movement Alerts - Улправда
HC Wainwright lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 from $30 - MSN
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction - Yahoo Finance
RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - The Malaysian Reserve
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Inves - GuruFocus
BioCryst reports inducement grants under Nasdaq listing rule - MSN
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
BioCryst Pharmaceuticals Q2 2025 Earnings Preview - MSN
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Look At 178% Potential Upside - DirectorsTalk Interviews
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biocryst Pharmaceuticals Inc Stock (BCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gayer Charles K | President and CCO |
Dec 22 '25 |
Option Exercise |
5.01 |
74,233 |
371,896 |
952,583 |
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):